Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $64.00. The company’s shares closed yesterday at $22.88.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Recursion Pharmaceuticals, and Xencor. According to TipRanks, Stranahan has an average return of -10.0% and a 37.10% success rate on recommended stocks.
Janux Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $76.57.
The company has a one-year high of $71.71 and a one-year low of $22.48. Currently, Janux Therapeutics Inc has an average volume of 970.1K.
Read More on JANX:
- Janux Therapeutics Holds 2025 Annual Stockholders Meeting
- Promising Developments and Market Potential of Janux Therapeutics Inc.: A Focus on JANX007 and JANX008 Trials
- Janux appoints Janeen Doyle chief corporate, business development officer
- Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion
- JANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?